Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01470417 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01470417 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 10 participants.
The verdict
NCT01470417, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will evaluate the role of Gemcitabine and Abraxane in the treatment of resectable and borderline-resectable pancreatic cancer by giving the chemotherapy before surgery.
Interventions
- DRUG Chemotherapy
- DRUG Chemotherapy + ChemoRadiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-10 |
| Est. Completion | 2019-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01470417
The ClinicalTrials.gov registry entry for NCT01470417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Chemotherapy is the first listed.
NCT01470417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01470417 about?
NCT01470417 is a clinical study titled "Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma". This study will evaluate the role of Gemcitabine and Abraxane in the treatment of resectable and borderline-resectable pancreatic cancer by giving the chemotherapy before surgery.
What is the current status of trial NCT01470417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2011-10. Estimated completion is 2019-10.
What interventions are being tested in trial NCT01470417?
The interventions under investigation include: Chemotherapy (DRUG), Chemotherapy + ChemoRadiotherapy (DRUG).
Who is sponsoring clinical trial NCT01470417?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.